- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Aclaris Therapeutics Inc(ACRS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ACRS
11/20/2026: ACRS (4-star) is currently NOT-A-BUY. Pass it for now.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel drug candidates for immuno-inflammatory and dermatological conditions. The company's primary strength lies in its promising biologic pipeline, including assets like bosakitug and ATI-052, supported by an experienced leadership team. Its core investment narrative centers on anticipated clinical trial readouts that could validate its targeted approach and attract partnership interest. However, the company faces substantial execution risks, ongoing net losses, and fierce competition from well-funded biotechnology peers. Aclaris best suits growth-oriented or risk-tolerant investors willing to monitor clinical milestones, regulatory updates, and cash runway management.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers long-term clinical growth potential if its novel immunology pipeline succeeds, but lacks predictable commercial revenue today. |
| Momentum investor | Strong fit while signal remains positive | Momentum is highly sensitive to upcoming clinical data readouts and positive regulatory or trial catalysts. |
| Value investor | Weak fit | Traditional value metrics do not apply given ongoing net losses and pre-commercial pipeline valuation. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all cash to fund clinical research. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks carry high price volatility and binary clinical trial risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Stock prices react sharply to clinical trial updates, regulatory milestones, and broader biotech sentiment. |
| Valuation risk | Medium / high | Valuation depends heavily on subjective future clinical probabilities rather than current earnings. |
| Competition risk (biologics and immunology) | High | Aclaris competes against heavily funded pharmaceutical firms developing similar immunology treatments. |
| Business quality | Medium | The company has strong scientific platforms and experienced leadership, but lacks commercial commercialized assets. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Success relies entirely on successfully executing complex clinical trials and securing capital. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 555.14M USD | Price to earnings Ratio - | 1Y Target Price 9.82 |
Price to earnings Ratio - | 1Y Target Price 9.82 | ||
Volume (30-day avg) 2.8M shares | Beta 0.94 | 52 Weeks Range 2.46 - 6.60 | Updated Date 11/20/2026 |
52 Weeks Range 2.46 - 6.60 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 84.62% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| License Fees and Royalties | Milestone payments and royalties generated from out-licensed dermatological or drug discovery assets partnering with larger pharmaceutical firms. | Revenue is currently sporadic and minor, meaning the stock trades primarily on clinical trial progress rather than product sales. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 440.85M | Price to Sales(TTM) 86.73 |
Enterprise Value 440.85M | Price to Sales(TTM) 86.73 | ||
Enterprise Value to Revenue 69.12 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 158.61M | Shares Floating 106.12M |
Shares Outstanding 158.61M | Shares Floating 106.12M | ||
Percent Insiders 6.77 | Percent Institutions 87.58 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

